Metabolic enzyme promotes neuroblastoma aggressiveness

(Boston University School of Medicine) High-risk neuroblastoma is an aggressive childhood cancer with poor treatment outcomes. Despite intensive chemotherapy and radiotherapy, less than 50 percent of these children survive for five years. While the genetics of human neuroblastoma have been extensively studied, actionable therapeutics are limited.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news